CORRECTION article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1681008
Correction《Triple Therapy Revolutionizes Treatment Paradigms for Previously Untreatable HCC Complicated by High-Flow Hepatic Arteriovenous Fistulas》
Provisionally accepted
- 1Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
- 2Laizhou Hospital of Traditional Chinese Medicine, yantai, China
- 3Linqing People's Hospital, Liaocheng, China
- 4Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
• Please read through all the templates before choosing • Pick the most relevant text template(s) from the following page and delete all others. • Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).''
Keywords: Hepatocellular Carcinoma, High-flow hepatic arteriovenous fistula, Hepatic arterial infusion chemotherapy, immune checkpoint inhibitors, tyrosine kinase inhibitors
Received: 06 Aug 2025; Accepted: 07 Aug 2025.
Copyright: © 2025 Li, Li, Zhong, Du, Chen, Shi, Zhao and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jinpeng Li, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
Lujun Zhao, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.